Regeneron Pharmaceuticals, Inc. (REGN) Wins FDA Approval for Livsayis in gMG

Regeneron (REGN) received FDA approval for Livsayis, a treatment for AChR-positive generalized myasthenia gravis. It is the first siRNA therapy and only gMG treatment dosed subcutaneously four times a year. The approval marks an early commercial milestone for Regeneron's first approved siRNA therapy and neurology medicine. The EU regulatory decision is expected in the second half of 2027.

Original reporting
Published Nov 18, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Regeneron Pharmaceuticals, Inc. (REGN) Wins FDA Approval for Livsayis in gMG — source image
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The approval could add a multi‑billion‑dollar revenue stream over the next decade if uptake meets expectations.

02

Market read

Regeneron's stock is expected to react positively to the FDA approval, with broader implications for RNA‑based therapeutics.

03

What to watch

Potential pricing pressure from insurers and the need for post‑approval real‑world data

Relevance 7/10Novelty 9/10Timing: today

Background

Regeneron announced its first siRNA therapy for a neurology indication, expanding beyond its antibody portfolio.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

FDA approved Regeneron's siRNA therapy Livsayis for adult AChR‑positive generalized myasthenia gravis.

Expected impact

likely upward pressure as investors price in new revenue potential

Evidence & confidence

First FDA‑approved siRNA for gMG, limited competition and quarterly dosing could drive strong uptake.

Market effects

strengthens the biotech/siRNA sector and may boost peers developing RNA‑based therapies

U.S. biotech market gains from a high‑profile FDA approval

sets a precedent for siRNA treatments in autoimmune diseases worldwide

Counterpoint

Market may have already priced in the approval; execution risk and reimbursement uncertainty could limit upside

Key entities

  • Regeneron Pharmaceuticals, Inc.

    US‑listed biotech firm developing Livsayis

  • FDA

    U.S. Food and Drug Administration granting approval

Related articles

MedAI 8/10

Profits jump 20% at Irish arm of US biotech Regeneron

Regeneron's Irish arm saw a 20% profit increase to $4.91B in 2025, with revenues up 3% to $12.53B. The company paid $716.6M in taxes and $5.3B in dividends. Key drugs Dupixent, Eylea HD, and Libtayo showed strong sales growth. Manufacturing was briefly disrupted due to repairs.

$REGNMed

European Commission approves flexible dosing for Regeneron’s Libtayo

Regeneron Pharmaceuticals (NASDAQ:REGN) received European Commission approval for a flexible dosing schedule for Libtayo (cemiplimab) across six cancer indications. The new regimen allows a 700 mg dose every six weeks after initial treatment, and reduced infusion times. The approval is based on clinical data and modeling. A U.S. review is ongoing, with a decision expected in March 2027.

$REGNMedAI 8/10

Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trial

Regeneron's Phase 2 trial for baloncibart (REGN7544) in POTS patients showed significant heart rate reduction at day 8, with the 450-mg dose maintaining benefits at day 29. The company plans to initiate Phase 3 trials in early 2025. According to Regeneron, the drug was generally well-tolerated, and improvements in physical functioning were observed in the higher dose group.